25 LLC’s Gilead Sciences GILD Stock Holding History

25 LLC’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7	Closed	-$537	–	222
2023 Q2	$537	Buy	+7	New	+$558	﹤0.01%	478

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

25 LLC's GILD Position: Q3 2023 in Review

25 LLC sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 7 shares — an estimated $537 sold.

25 LLC first reported a position in GILD in Q2 2023 and held it in 1 quarter. The position peaked at $537 in Q2 2023. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

25 LLC reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
25 LLC sold 7 Gilead Sciences shares in Q3 2023, an estimated $537.
25 LLC first reported a position in Gilead Sciences in Q2 2023 and held it in 1 quarter.
25 LLC's Gilead Sciences position peaked at $537 in Q2 2023.
1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.